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ABSTRACT 
Background & Aims: Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory 
disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived 
human monoclonal antibody against the interleukin 4 (IL4) receptor, inhibits IL4 and IL13 
signaling. Dupilumab is effective in treatment of allergic, atopic, and type 2 diseases, so we 
assessed its efficacy and safety in patients with EoE. 
 
Methods: We performed a phase 2 study of adults with active EoE (2 dysphagia episodes of 
dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils per high-
power field), from May 12, 2015 through November 9, 2016 at 14 sites. Subjects were randomly 
assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg; n=23) or 
placebo (n=24) for 12 weeks. The primary endpoint was change from baseline to week 10 in 
Straumann dysphagia instrument patient-reported outcome (SDI-PRO) score. We also assessed 
histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic 
scores), endoscopically visualized features (endoscopic reference score), esophageal 
distensibility, and safety. 
 
Results: The mean SDI-PRO score was 6.4 when the study began. In the dupilumab group, SDI-
PRO scores were reduced by a mean value of 3.0 at week 10 compared with vs a mean reduction 
of 1.3 in the placebo group (P=.0304) At week 12, dupilumab reduced peak esophageal 
intraepithelial eosinophil count by a mean 86.8 eosinophils per high-power field (reduction of 
107.1%; P<.0001 compared with baseline), the EoE-HSS severity score by 68.3% (P<.0001 vs 
baseline), and the endoscopic reference score by 1.6 (P=.0006 compared with baseline. 
Dupilumab increased esophageal distensibility by 18% compared with baseline (P<.0001). 
Higher proportions of patients in the dupilumab group developed injection-site erythema (35% 
vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the placebo group). 
 
Conclusions: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, 
histologic features of disease (including eosinophilic infiltration and a marker of type 2 
inflammation), and abnormal endoscopic features, compared with placebo. Dupilumab increased 
esophageal distensibility and was generally well tolerated. ClinicalTrials.gov no: NCT02379052 
 
KEY WORDS:  EREFS, HSS, food allergy, esophagus 
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Eosinophilic esophagitis (EoE) is a chronic inflammatory disease characterized by esophageal dysfunction 
and eosinophilic inflammation in the esophagus; it is thought to be triggered by an abnormal type 2 
immune response to food allergens.1,2  
Adult patients with EoE have substantially impaired quality of life due to, among other things, dysphagia 
and the risk of food impaction.3 They have increased levels of esophageal inflammatory infiltrates, 
including eosinophils, T cells, mast cells, and basophils, as well as type 2–associated inflammatory 
chemokines and cytokines, including eotaxin-3, interleukin-4, interleukin-5, and interleukin-13.4,5 
Chronic esophageal inflammation leads to remodeling, stricture formation, and fibrosis, with 
commensurate worsening of dysphagia.6-8 Patients with EoE demonstrate a marked reduction in 
esophageal distensibility associated with adverse outcomes of food impaction and requirement for 
esophageal dilation.9 The pooled incidence rate of EoE in a meta-analysis of 13 population-based studies 
from around the world (North America, Europe, and Australia) on the epidemiology of EoE in adults and 
children was 3.7/100,000 persons/year, and the pooled prevalence was 22.7/100,000 inhabitants.10 In 
the United States, the prevalence of EoE in adults ranges from 40 to 90 cases per 100,000 persons.11 
Current standard of care for EoE consists of food elimination diets, off-label use of swallowed topical 
corticosteroids, high-dose proton pump inhibitor (PPI) therapy in PPI-responsive phenotypes, and 
esophageal dilation.1 However, these therapies can be limited by variable response rates, relapse after 
therapy cessation, and adverse effects on quality of life. These potential limitations highlight the need 
for new treatments targeting key pathways driving EoE inflammation.12-14 To date, the US Food and Drug 
Administration has not approved pharmacologic therapies for EoE; the European Medicines Agency 
recently approved budesonide orodispersible tablets for the treatment of EoE in adults.15 
Dupilumab is a fully human VelocImmune®-derived monoclonal antibody16,17 directed against the 
interleukin-4 receptor-α component of the type 2 receptor, and inhibits signaling of both interleukin-4 
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and interleukin-13.18 The efficacy of dupilumab in several settings of allergic/atopic/type 2 disease 
demonstrates that interleukin-4 and interleukin-13 are key initiators of type 2 inflammation. Dupilumab 
has shown efficacy in pediatric and adult atopic dermatitis,19-22 asthma,23-25 and chronic sinusitis with 
nasal polyposis,26 and is also being studied as an adjunct for peanut and grass allergy desensitization.27 
Therapeutics targeting interleukin-5 have shown efficacy in asthma, but have failed in other settings of 
allergic/atopic/type 2 disease, such as atopic dermatitis and EoE.13,28,29 Following the efficacy of 
dupilumab observed in multiple settings of allergic/atopic/type 2 diseases, we investigated the efficacy 
and safety of dupilumab vs placebo in adults with active EoE.  
 8 
 
METHODS 
STUDY DESIGN AND OVERSIGHT 
This was a multi-center, randomized, double-blind, parallel-group, placebo-controlled phase 2 study of 
dupilumab in adults with active EoE. The study was conducted between May 2015 and July 2017 at 14 
study sites in the United States. The study consisted of a 35-day screening period, a 12-week 
randomized treatment period, and a 16-week post-treatment follow-up period (see Supplementary 
Figure 1). Efficacy was assessed based on clinical signs and symptoms evaluated using EoE-specific 
patient-reported outcome (PRO) measures and based on histologic and endoscopic findings, including 
distensibility assessment. Technical problems with the electronic diary used for collecting PROs resulted 
in data loss and required a change in the primary endpoint from Week 12 to Week 10; this amendment 
was made before unblinding and was included in both the study protocol and the statistical analysis 
plan. All other measures, including histologic endpoints, endoscopically visualized features, distensibility 
measures of esophageal function, and quality-of-life endpoints that were not captured electronically 
were evaluated at Week 12. 
The protocol (see Supplementary Appendix) was developed by the sponsors (Sanofi and Regeneron 
Pharmaceuticals, Inc.). Data were collected by the investigators and analyzed by the sponsors. The study 
was conducted in accordance with the Declaration of Helsinki, International Conference on 
Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. An 
independent data and safety monitoring committee conducted blinded monitoring of patient safety 
data. The local institutional review board or ethics committee at each study center oversaw trial conduct 
and documentation. All patients provided written informed consent before participating in the trial.  
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All authors had access to the study data, and participated in the interpretation of the data. They each 
provided input and critical feedback to the drafting of the manuscript, approved the final manuscript, 
and take responsibility for the accuracy and completeness of the data and analyses. All investigators had 
confidentiality agreements with the sponsors, Sanofi and Regeneron Pharmaceuticals. The manuscript 
drafts were prepared with the assistance of a medical writer paid by the sponsors. 
PATIENTS 
Adults (ages 18–65 years) with documented EoE who were nonresponsive to PPIs and were diagnosed in 
accordance with consensus guidelines30 were eligible to participate. Active esophageal inflammation 
was to be evident at screening (ie, a peak cell count ≥15 eosinophils per high-power field [eos/HPF]: 
400X magnification of a 0.3mm2 field) as indicated by esophageal pinch biopsy specimens from at least 2 
of 3 esophageal sites from endoscopy performed no more than 2 weeks after at least 8 weeks’ 
treatment with high-dose (or twice-daily dosed) PPIs. Patients were also required to have a patient-
reported history of an average of ≥2 episodes of dysphagia per week in the 4 weeks before screening, 
with a Straumann Dysphagia Instrument (SDI)31 PRO score ≥5 at screening and baseline, and a 
documented history or presence of ≥1 type 2 comorbid atopic disease. The presence of atopy was 
required because at the time of the study design, dupilumab had documented efficacy in atopic 
dermatitis, and so an EoE study population enriched for other type 2/allergic/atopic conditions was 
considered to be the most likely responsive population. No patients screen-failed based on this criterion. 
Key exclusion criteria included esophageal stricture unable to be passed with a standard adult upper 
endoscope, esophageal dilation required at screening, and use of systemic glucocorticoids <3 months or 
swallowed topical glucocorticoids <6 weeks prior to screening. Detailed inclusion and exclusion criteria 
are provided in the Supplementary Appendix, Section 1. 
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TREATMENT AND PROCEDURES 
Patients were randomized 1:1 to receive weekly subcutaneous dupilumab 300 mg (loading dose, 600 mg 
on Day 1) or matching placebo during the 12-week, double-blind treatment phase. Randomization, 
stratified by baseline SDI score (≥5 and ≤7 vs >7),31 was conducted using a central interactive voice/web 
response system. Study patients, principal investigators, central pathology review pathologists, and 
study site personnel remained blinded to all randomization assignments during the double-blind 
treatment period of the study. Blinded study drug kits coded with a medication numbering system were 
used, and lists linking these codes with product lot numbers were not accessible to individuals involved 
in study conduct. Patients were instructed not to modify their diets during the study. Patients could 
receive concomitant medications as needed at the investigator’s discretion, except for those that were 
prohibited (Supplementary Appendix, Section 2), while continuing study treatment. Patients using stable 
doses of PPIs at screening were permitted to continue on the same dosing regimen until the end-of-
treatment visit; those not using PPIs in the 8 weeks prior to screening were prohibited from starting 
them. If medically necessary, rescue medications or emergency esophageal dilation could be provided. 
Patients who received rescue therapy were discontinued from study treatment and considered 
nonresponders. Study assessments were performed weekly from Weeks 1 to 12 and every 4 weeks 
during the 16-week follow-up. 
ENDPOINTS 
The primary efficacy endpoint was the change in SDI PRO dysphagia score31 from baseline to Week 10. 
Secondary SDI PRO endpoints included percentage change in SDI PRO score from baseline to Week 10 
and percentage of patients with a SDI PRO score decrease of ≥3 points relative to baseline at Week 10, 
which was proposed by Straumann and colleagues as evidence of a clinical response.31 Other secondary 
endpoints, primarily evaluated at Week 12, included histologic measures of type 2 inflammation in the 
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esophagus (as measured by esophageal intraepithelial eosinophilia), endoscopically visualized 
anatomical measures of esophageal disease (ie, exudate, rings, edema, furrows, and strictures), 
distensibility measures of esophageal function, as well as additional PROs. These endpoints were 
assessed by measuring percentage change in peak esophageal intraepithelial eos/HPF from baseline to 
Week 12, and change in EoE Endoscopic Reference Scoring system (EREFS) score6,32 from baseline to 
Week 12.  
Other secondary efficacy endpoints were percentage of patients requiring rescue medication or a 
procedure (eg, esophageal dilation) through Week 12, and the PRO and quality-of-life endpoints of 
absolute and percentage change in weekly Eosinophilic Esophagitis Activity Index (EEsAI) PRO score33 
from baseline to Week 10, percentage of patients with ≥40% improvement33 or ≥15- or ≥30-point 
improvement in EEsAI PRO score from baseline to Week 10, and change in Adult Eosinophilic Esophagitis 
Quality of Life (EoE-QOL-A) score v.3.034,35 from baseline to Week 12. Symptomatic remission of EoE, 
defined as an EEsAI score of ≤20 at Weeks 10 and 12, was also assessed in a post hoc analysis, as were 
the proportions of patients who achieved both histologic (<6 eos/HPF at Week 12) and symptomatic 
remission (SDI score reduction of of ≥3 points relative to baseline at Week 10) and both histologic and 
endoscopic remission.36 Safety was evaluated by incidence of treatment-emergent adverse events 
(TEAEs) and serious adverse events (SAEs) from baseline to Week 28.  
Exploratory histology endpoints were change in LS mean peak esophageal intraepithelial eosinophil 
count (eos/HPF) (calculated using peak counts from each esophageal site) from baseline to Week 12, 
proportion of patients who achieved peak esophageal intraepithelial eosinophil count <1 eos/HPF at 
Week 12, proportion of patients who achieved peak esophageal intraepithelial eosinophil count ≤6 
eos/HPF37 and <15 eos/HPF (post hoc analysis), and change in EoE histology scoring system (EoE-HSS) 
from baseline to Week 12.38 An exploratory endpoint was change in esophageal distensibility plateau, 
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measured by functional luminal imaging probe (EndoFLIP®, Medtronic, Minneapolis, MN),39,40 from 
baseline to Week 12. 
The full list of protocol prespecified endpoints is provided in Supplementary Table 1. 
STATISTICAL ANALYSIS 
A sample size of 18 patients per treatment arm was calculated to provide 94% power to detect a 
clinically meaningful treatment effect, with an expected mean difference of a 3-point change from 
baseline to Week 12 in SDI score between dupilumab and placebo in a 2-sided t-test with 5% 
significance and an assumed standard deviation of 2.46.31 Taking into account an assumed 15% dropout 
rate, 22 patients per treatment arm were to be enrolled. The primary and secondary efficacy endpoints 
were analyzed in the full analysis set, which included all randomized patients. The analysis was 
conducted using multiple imputation for missing data, with an analysis of covariance (ANCOVA) model 
with treatment as a fixed effect, and baseline SDI value and relevant baseline value as continuous 
covariates (only for secondary efficacy analysis). Due to a substantial imbalance at baseline in the 
number of patients in the 2 randomization strata (only 13% of patients in the strata of baseline SDI >7), 
the ANCOVA model did not use randomization strata as a factor, but instead included baseline SDI value 
as a continuous covariate. 
TEAEs were defined as any untoward medical occurrence during the treatment period. SAEs were 
defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, 
required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or 
significant disability/incapacity, or was an important medical event. 
Categorical analyses were performed on responder data; comparisons between dupilumab and placebo 
used Fisher’s exact test. Patients with early withdrawal or use of rescue medication or procedure were 
counted as nonresponders subsequent to the withdrawal or rescue. 
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All analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, NC). The full statistical 
methodology is summarized in Supplementary Appendix, Section 3.  
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RESULTS 
PATIENTS 
Between May 12, 2015 and November 9, 2016, 80 patients were screened for study eligibility; of these, 
47 (59%) were subsequently randomized (23 dupilumab, 24 placebo) at 14 study sites in the United 
States and received ≥1 dose of study medication (Supplementary Figure 2). Failing to meet eligibility 
criteria was the main reason for screen failure (32/33 patients [97%]), in particular, inadequate 
frequency of dysphagia, failure to meet histologic criteria, failure to meet stabilized diet for at least 6 
weeks criteria, and failure to meet signing informed consent criteria; one patient withdrew consent. 
Baseline characteristics were generally well balanced between the groups, except for mean total 
immunoglobin E (IgE), which was higher in the placebo group (Table 1 and Supplementary Table 2). 
Most patients (79% and 87% for placebo and dupilumab groups, respectively) had ≥2 additional 
comorbid atopic diseases, 42% and 48%, respectively, had prior esophageal dilation, and 38% and 30% 
of placebo- and dupilumab-treated patients, respectively, had previously used oral or systemic 
glucocorticoids for their EoE treatment. Patients reported a history of an average ≥2 episodes of 
dysphagia per week in the 4 weeks before screening and in the time period between screening and 
baseline. In placebo- and dupilumab-treated patients, respectively, the mean (SD) weekly baseline SDI 
PRO score was 6.4 (1.01) and 6.4 (1.04), mean (SD) baseline EREFS was 4.3 (1.46) and 3.9 (1.87), and 
mean (SD) baseline peak eosinophil count was 101.1 (57.12) and 102.1 (53.46) eos/HPF. The numbers of 
patients with missing values for the primary and secondary efficacy endpoints are provided in 
Supplementary Table 3. 
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PRIMARY OUTCOME 
As mentioned in the Methods section, technical problems with the electronic diary (identified prior to 
database lock) resulted in significant data loss by Week 12 and necessitated assessment of the primary 
endpoint at Week 10 rather than Week 12. The number of patients with missing values for both the 
primary and secondary efficacy endpoints are provided in Supplementary Table 3. For completeness, an 
analysis of the primary endpoint is presented below for observed values only, with no imputation of 
missing data (ie, n = 14 of 24 placebo-treated patients; n = 17 of 23 dupilumab-treated patients).  
At Week 10, dupilumab significantly improved the SDI PRO score from baseline (least squares [LS] mean 
change, −3.0 vs −1.3 for placebo; P=.0304) (Figure 1A and Table 2). In dupilumab-treated patients, 
improvements in SDI PRO scores were observed as early as Week 1 (Supplementary Figure 3). This 
finding was supported by the analysis of the primary endpoint using observed values regardless of 
rescue treatment use with no imputation of missing data. At Week 10, dupilumab significantly improved 
the SDI PRO score from baseline (LS mean change, −3.2 vs −1.1 for placebo; P=.0226) (Supplementary 
Table 4). 
Overall, outcomes of 3 prespecified sensitivity analyses, which include different imputation methods (ie, 
LOCF and WOCF) and all observed values regardless of rescue treatment use, were similar to those of 
the primary analysis (Supplementary Table 5). 
SECONDARY SDI PROs 
At Week 10, the LS mean percentage change from baseline in SDI score was also significantly improved 
with dupilumab (−45.1 vs −18.6 for placebo; P=.0312) (Figure 1B and Table 2). Nine (39%) dupilumab-
treated patients showed a reduction in SDI PRO score of ≥3 vs 3 (13%) patients in the placebo group at 
Week 10 (LS mean difference vs placebo, 26.6% [95% CI, −3.0 to 51.1; P=.0490]; Table 2). 
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SECONDARY HISTOLOGY, EXPLORATORY HISTOLOGY, AND ENDOSCOPY OUTCOMES 
Esophageal intraepithelial eosinophil counts relative to baseline were decreased at Week 12 in all 23 
(100%) dupilumab-treated patients (Supplementary Figure 4). Relative to placebo, the LS mean 
reduction from baseline to Week 12 in peak esophageal intraepithelial eosinophil count was 86.8 
eos/HPF (95% CI, −113.2 to −60.5; P<.0001) (Table 2; Supplementary Figure 5). The LS mean (SE) peak 
esophageal intraepithelial eosinophil count was reduced by 92.9% (12.1) in patients receiving dupilumab 
treatment and was increased by 14.2% (12.5) in patients receiving placebo (P<.0001 vs placebo). The 
proportions of dupilumab-treated patients with esophageal intraepithelial eosinophil counts of ≤6 
eos/HPF and <15 eos/HPF vs placebo at Week 12 were 65% vs 0% (P<.0001 vs placebo) and 83% vs 0% 
(P<.0001 vs placebo), respectively (Table 2; Supplementary Figure 6). In dupilumab-treated patients, 
13% had a response of <1 eos/HPF at Week 12 vs 0% in the placebo arm (P=.1092 vs placebo).  
Dupilumab treatment improved EoE-EREFS total scores by −1.6 (95% CI,−2.5 to −0.7; P=.0006) vs placebo 
at Week 12 (Table 2, Figure 1C). 
Compared with placebo, dupilumab treatment led to a reduction in total EoE-HSS severity score (grade; 
LS mean % change −68.3 [95% CI, −86.2 to −50.3; P<.0001]) and total EoE-HSS extent score (stage; LS 
mean % change −54.6 [95% CI, −68.1 to −41.0; P<.0001]) that take into account histologic findings for all 
regions (proximal, mid, and distal) of the esophagus at Week 12 (Table 2 and Figures 1D and 1E). The 
representative esophageal mucosal pinch biopsies collected at baseline and Week 12 are shown in 
Supplementary Figure 2.  
Compared with placebo, dupilumab use also improved esophageal distensibility plateau by 18.0% (2.9 
mm) (95% CI, 10.9 to 25.2; P<.0001) at Week 12 (Table 2 and Figure 1F). Analyses for all observed values 
are provided in Supplementary Table 5. 
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SECONDARY PROs AND QUALITY-OF-LIFE OUTCOMES 
Dupilumab treatment provided a numerical improvement in percentage change in weekly EEsAI PRO 
score of –23.2% (95% CI, –49.7 to 3.2; P=.0850) vs placebo at Week 10. These improvements were 
observed as early as Week 1 (Table 2, Supplementary Figure 7). The proportion of patients with ≥40% 
improvement from baseline to Week 10 in EEsAI score was 26% with dupilumab vs 8% with placebo 
(difference vs placebo, 17.8%; 95% CI, −11.5 to 43.6; P=.1365) (Table 2). Significantly more dupilumab- 
vs placebo-treated patients were in symptomatic remission at Weeks 10 and 12, as defined by an EEsAI 
score ≤20,35 (risk difference vs placebo, 21.9% [95% CI, 2.3 to 41.6; P=.0479] and 21.7% [95% CI, 4.9 to 
38.6; P=.0219], respectively, Table 2). 
At Week 12, a numerical improvement of 0.3 (95% CI, −0.1 to 0.7; P=.0910) was observed for total EoE-
QOL-A scores with dupilumab vs placebo (Table 2). Numerical but nonsignificant improvements were 
also observed for each of the individual domains that comprise the EoE-QOL-A. No patient in either 
treatment group received rescue medication or any other interventional procedure such as esophageal 
dilatation during the 12-week treatment period or in the 16-week follow-up period.  
PATIENTS ACHIEVING HISTOLOGIC PLUS SYMPTOMATIC REMISSION 
The proportions of patients acheiving histologic remission (3 regions with eos/HPF <6 at Week 12) as 
well as symptomatic remission (SDI score reduction of ≥3 points at Week 10) were 13% and 0% for 
dupilumab- and placebo-treated patients, respectively (risk difference [95% CI] vs placebo, 13.0 [−0.7 to 
26.8]; P=.1092). The proportions of patients with histologic remission at Week 12 as well as 
symptomatic remission (EEsAI score ≤20 at Week 10) were 4.3% and 0% for dupilumab- and placebo-
treated patients, respectively (risk difference [95% CI] vs placebo, 4.3 [−4.0 to 12.7]; P=.4894). 
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SAFETY 
Dupilumab was well tolerated during the study period. During the 12-week treatment period, the most 
frequently occurring TEAEs (as defined by the Medical Dictionary for Regulatory Activities [MedDRA] 
preferred term) occurring in ≥3 patients in either the dupilumab or placebo groups were nonserious 
injection-site erythema (35% vs 8%, respectively) and nasopharyngitis (17% vs 4%, respectively) 
(Table 3). Injection-site reactions by MedDRA high-level terms were reported in 13 (57%) dupilumab-
treated patients vs 7 (29%) placebo-treated patients. There were no serious TEAEs or deaths during the 
12-week treatment period. One dupilumab-treated patient (4.3%) discontinued treatment due to a TEAE 
(nail disorder; see Supplementary Appendix for patient narrative). Three serious TEAEs that were 
considered to be unrelated to the investigational medicinal product occurred in dupilumab-treated 
patients during the safety follow-up phase after the 12-week treatment period: food allergy in 1 patient, 
creatine phosphokinase elevation in 1 patient, and spontaneous abortion in 1 patient (see 
Supplementary Appendix for patient narrative). During the treatment period, conjunctivitis was 
observed in neither dupilumab- nor placebo-treated patients, despite a prior history of conjunctivitis in 
3 patients in each group. In this study, no cases of hypereosinophilia were observed in dupilumab-
treated EoE patients. TEAEs during the entire study period including the 16-week follow-up period are 
presented in Supplementary Table 6. 
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DISCUSSION 
Dupilumab treatment significantly improved dysphagia, severity of histologic and endoscopic features, 
esophageal intraepithelial eosinophil count, and esophageal distensibility, with a trend toward reducing 
symptoms and improving quality of life compared with placebo. Dupilumab reduced both the frequency 
and severity of dysphagia events,41 with concurrent reductions in mucosal eosinophil density and 
macroscopic manifestations ascertained by the validated EREFS endoscopic visualization score.6,39 In 
addition, dupilumab improved most components of the EoE-HSS, a recently validated histologic score 
that measures other histologic abnormalities in addition to the density of eosinophilic inflammation.38,42 
Significant improvements in EEsAI PRO symptom score vs placebo were also observed with dupilumab 
treatment, which supported the histologic findings of decreased esophageal eosinophilia and increased 
distensibility with dupilumab treatment, consistent with a reduction in remodeling and improved 
esophageal function.39 These results demonstrate that interleukin-4 and interleukin-13 are central 
pathological mediators of esophageal inflammation and dysfunction in adult patients with active EoE. 
Studies with other targeted biologic agents have failed to demonstrate significant improvement in 
dysphagia relative to placebo, even upon reduction of peak eosinophil count, suggesting that factors 
other than eosinophils are involved in the esophageal remodeling and dysfunction in adult EoE. 
Mepolizumab and reslizumab (anti-interleukin-5) reduced esophageal intraepithelial eosinophil counts, 
but did not significantly improve symptoms compared with placebo.13,28,29 Interleukin-13–specific 
inhibitors (QAX576, RPC4046) improved histologic features of EoE, but also did not resolve symptoms. 
QAX576 improved esophageal intraepithelial eosinophil counts and the EoE-associated transcriptome, 
but not dysphagia.12 RPC4046 significantly reduced EoE-EREFS and esophageal eosinophil counts with 
nonsignificant trends for dysphagia symptom improvement.43 Omalizumab (anti-IgE mAb) did not 
improve either dysphagia or histologic features of EoE compared with placebo, suggesting pathogenesis 
is not mediated by IgE, despite the association of EoE with comorbid allergies.44  
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In this proof-of-concept study, dual blockade of interleukin-4 and interleukin-13 signaling with 
dupilumab improved both esophageal inflammation and clinical symptoms in patients with EoE. These 
data provide further evidence for the importance of interleukin-4/interleukin-13 pathways in type 2 
inflammation and suggest that their dual inhibition may be a more effective inhibitor of type 2 
inflammation than interleukin-5, interleukin-13, or IgE-targeted agents alone. The more fundamental 
roles of interleukin-4 and interleukin-13 in driving allergic/atopic/type 2 inflammation is similarly 
reflected by its broader activity in type 2 diseases (compared with other targeted agents), not only in 
EoE, but also in atopic dermatitis, as well as in its ability to significantly improve lung function in asthma 
patients.  
The high rate of screen failures observed in our study (41%) is consistent with other recently published, 
randomized controlled trial data in eosinophilic esophagitis. The United States trials are enrolling 
patients with very high levels of symptoms and histologic activity, who represent a discrete subset of 
patients with EoE. In the recent trial of budesonide oral suspension,37 203 patients were enrolled and 81 
patients were screen failures. In our study, the most common reason for screen failure was failing to 
meet eligibility criteria (32 of 33 patients), in particular, inadequate frequency of dysphagia, failure to 
meet histologic criteria, failure to meet stabilized diet for at least 6 weeks criteria, and failure to meet 
signing informed consent criteria. 
This study has a number of limitations and strengths. At the time the study was designed, the only 
published data available for dysphagia response were for SDI PRO scores.31 None were available for the 
EEsAI, a PRO measure designed and validated for use in EoE, therefore size calculations could not be 
performed. Change from baseline in SDI PRO score was therefore chosen as the primary efficacy 
endpoint and, although the SDI is not a validated instrument, the results obtained were in line with 
those observed with the EEsAI. The study was small, and the results obtained are mainly limited to 
patients with mild-to-moderate esophageal symptoms, since at baseline there was an imbalance in the 
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recruitment of patients with an SDI score >7 (only 13% of all recruits); interpretation of the findings in 
patients with more severe disease should therefore be made with caution. In addition, some patients 
had missing data for evaluation of SDI and EEsAI PRO scores due to an e-diary data capture issue. To 
diminish any potential bias as a result of data loss, we used multiple imputation methods, and even with 
the data loss, statistically significant symptom improvements were observed in the primary endpoint, 
which were consistent across a range of sensitivity analyses. Though the functional lumen imaging probe 
procedure in EoE (EndoFLIP®) was exploratory in nature, dupilumab treatment also significantly 
improved esophageal distensibility.40 The study had a short treatment duration (12 weeks), so long-term 
efficacy remains to be evaluated. Enrollment of highly symptomatic patients from tertiary care centers 
limits the generalizability of these findings, and the prior glucocorticoid or elimination-diet 
responsiveness was not assessed. Furthermore, the great majority of patients (83%) had ≥2 comorbid 
atopic diseases, suggesting that the applicability of the data is likely restricted to EoE patients with 
comorbid type 2 conditions, rather than EoE alone. The strengths of this study include the use of 
centralized histologic assessment, multiple objective scoring systems (including the validated EoE-HSS, 
EEsAI PRO scores, and EREFS endoscopic grading and classification system), the use of the functional 
lumen imaging probe (EndoFLIP®) to measure esophageal distensibility, and the highly consistent 
improvements across all assessments. 
Dupilumab was generally well tolerated, although nonserious injection-site erythema and 
nasopharyngitis occurred more frequently in dupilumab-treated patients; increase in nasopharyngitis 
has not been noted across dupilumab studies involving thousands of patient years. Observed safety is 
consistent with published studies of dupilumab.20-26 
To ascertain whether any relationships exist between clinical symptoms and endoscopic or histologic 
features in patients with EoE, we conducted a series of post hoc correlation analyses on the data from 
this study. Both endoscopic (EoE-EREFS) and histologic disease activity (EoE-HSS stage, EoE-HSS grade, 
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peak eosinophil count) were found to be significantly correlated with reduced esophageal distensibility 
in all patients at Week 12, suggesting an association between esophageal inflammation and function.41 
Significant correlations were also observed between EoE-EREFS and with both EoE-HSS stage and grade 
scores, but not with peak esophageal intraepithelial eosinophil count.45 Nonsignificant negative 
correlations were observed between baseline characteristic (SDI total score and frequency/number of 
dysphagia episodes vs disease activity at baseline [EREFS, EoE-HSS, peak eosinophils]).46 While these 
findings support the concept of evaluating both the severity and extent of multiple pathologic features 
in EoE biopsies, the sample size is small. Further correlation analyses are planned in a larger patient 
population with broader disease activity. 
In conclusion, dupilumab is the first targeted biologic agent to improve dysphagia, histologic and 
endoscopic measures of disease, as well as esophageal function, and have an acceptable safety profile in 
adult patients with active EoE. Further studies are required to determine the long-term efficacy and 
safety of dupilumab in the treatment of EoE. 
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FIGURES 
Figure 1. (A) LS mean change from baseline in SDI PRO score at Week 10. (B) LS mean percentage 
change in peak esophageal intraepithelial eosinophil count. (C) LS mean change in EoE-EREFS. (D) LS 
mean percentage change in EoE-HSS total grade score. (E) LS mean percentage change in EoE-HSS total 
stage score. (F) LS mean percentage change in distensibility at Week 12. Data EoE-EREFS, Eosinophilic 
Esophagitis Endoscopic Reference Score; EoE-HSS, eosinophilic esophagitis histology scoring system; LS, 
least squares; PRO, patient-reported outcome; SDI, Straumann Dysphagia Instrument; SE, standard 
error; n, number of patients with observed data; N, number of patients with imputed data. Missing data 
were imputed with multiple imputations.  
Figure 2. Esophageal mucosal pinch biopsies collected at baseline and Week 12. Basal zone hyperplasia 
(black bar), eosinophils (black arrow), surface layering (white arrow), dilated intercellular spaces (elbow 
connector arrow). Note apparent ablation of basal cell hyperplasia, complete depletion of eosinophils 
(and their surface layering), and elimination of dilated intracellular spaces at Week 12 following 
dupilumab treatment. 
 
TABLES  
Table 1. Demographics and Clinical Characteristics of the Patients at Baseline 
Characteristic Placebo 
(n = 24) 
Dupilumab 300 mg qw 
(n = 23) 
Age, mean (SD) — yr 36.1 (12.75) 33.1 (8.70) 
Male sex — no. (%) 10 (42) 13 (57) 
White race — no. (%) 21 (87.5) 23 (100) 
Prior esophageal dilations, mean (SD) — no. 3.9 (3.31) 5.7 (8.03) 
Any prior use of a glucocorticoid for EoE — no. (%) 9 (38) 7 (30) 
Prior history of treatment with high-dose PPIs at baseline — no. (%) 24 (100) 23 (100) 
PPI treatment ongoing at baseline 15 (62.5) 14 (60.9) 
Duration of eosinophilic esophagitis, mean (SD) — yr 5.0 (3.33) 3.6 (3.74) 
>1 comorbid atopic disease — no. (%) 19 (79) 20 (87) 
Food allergy
a
  17 (71) 14 (61) 
Allergic rhinitis  15 (63) 16 (70) 
Asthma  9 (38) 11 (48) 
Chronic rhinosinusitis 8 (33) 2 (9) 
Atopic dermatitis  5 (21) 3 (13) 
Allergic conjunctivitis  3 (13) 3 (13) 
Blood eosinophils, mean (SD) — x 10
9
/L 0.43 (0.29) 0.31 (0.18) 
Total IgE, mean (SD) — kU/L 486.2 (900.7) 217.8 (288.8) 
SDI PRO score, mean (SD) — scale 0−9
b
 6.4 (1.0) 6.4 (1.0) 
SDI PRO intensity score, mean (SD) 3.3 (0.46) 3.2 (0.39) 
SDI PRO frequency score, mean (SD)  3.1 (0.93) 3.3 (0.86) 
Peak esophageal eosinophil count (eos/HPF) of proximal, mid, distal regions, mean (SD) 101.1 (57.12) 102.1 (53.46) 
Proximal eosinophil count (eos/HPF), mean (SD) 50.5 (47.16) 49.2 (45.76) 
Mid eosinophil count (eos/HPF), mean (SD) 96.0 (59.73) 77.3 (41.67) 
Distal eosinophil count (eos/HPF), mean (SD) 69.2 (33.10) 75.2 (59.62) 
EoE-EREFS total score, mean (SD) — scale 0−8
c
 4.3 (1.46) 3.9 (1.87) 
EoE-HSS grade total score, mean (SD)
d
 27.6 (8.38) 28.5 (7.98) 
EoE-HSS stage total score, mean (SD)
d
 27.4 (6.46) 27.9 (6.05) 
Esophageal distensibility plateau, mean (SD), mm 17.6 (2.88) 18.7 (3.80) 
Weekly EEsAI PRO score, mean (SD) — scale 0−100
e
 62.2 (16.45) 62.0 (18.36) 
EoE-QOL-A
f
 3.11 (0.995) 3.02 (0.899) 
EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; EoE-EREFS, Eosinophilic Esophagitis Endoscopic Reference Score; EoE-HSS, 
eosinophilic esophagitis histology scoring system; eos/HPF, eosinophils per high-power field; PRO, patient-reported outcome; SD, standard 
deviation; SDI, Straumann Dysphagia Instrument; qw, once a week. 
aThe presence of food allergy was based on chart review and did not require formal allergy testing (see Supplementary Table 2 for breakdown). 
The specific foods queried would be expected to capture oral allergy syndrome (food-pollen syndrome) and not just food-related anaphylaxis. 
b
SDI PRO total score is the sum of scores of frequency of dysphagia and intensity of dysphagia; total score range 0−9 (higher scores indicate 
worse symptoms). The minimal clinically important difference is 3.
30 
c
The EoE-EREFS measures endoscopically identified EoE esophageal mucosal inflammatory and remodeling features; total scores for edema, 
rings, furrows, exudate, stricture range 0−8 (higher scores indicate greater impairment). 
d
The EoE-HSS measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, surface epithelial 
alteration, dyskeratotic epithelial cells, and dilated intercellular spaces; scale 0−63 (higher scores indicate more severe histologic findings). 
e
EEsAI PRO is a 5-component (10-item) measure of dysphagia, swallowing-associated pain, and strategies aimed at avoiding dysphagia episodes; 
total score range 0−100 (higher scores indicate worse symptoms). 
f
EoE-QOL-A questionnaire includes 30 items related to 5 established domains (eating/diet impact, social impact, emotional impact, disease 
anxiety, and swallowing anxiety) of daily life experiences using a 5-point Likert scale. The EoE-QOL-A score is the average obtained by dividing 
the total score by the number of questions (for patients without disease, 120/30 = 4). Total scores range from 1 to 5. 
 
 
  
Table 2. Primary, Secondary, and Exploratory Endpoints 
 Placebo  
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
Difference  
vs placebo (95% CI) 
P value vs placebo 
SDI PRO score
a
     
Week 10 — no./imputed no.  14/10 17/6   
LS mean change from baseline (SE) −1.3 (0.6) −3.0 (0.5) −1.7 (−3.2 to −0.2) .0304 
LS mean percentage change from baseline 
(SE) 
−18.6 (9.0) −45.1 (8.4) −26.5 (−50.5 to −2.4) .0312 
 
Patients with decrease of ≥3 points on the SDI 
from baseline to week 10 — no. (%)  
3 (13) 9 (39) 27 (−3 to 51) .0490 
Peak esophageal intraepithelial eosinophil 
count (eos/HPF)  
    
Week 12 — no./imputed no. 22/2 23/0   
LS mean change from baseline (SE) −8.0 (9.6) −94.8 (9.4) −86.8 (−113.2 to −60.5) <.0001 
 Placebo  
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
Difference  
vs placebo (95% CI) 
P value vs placebo 
LS mean % change from baseline (SE) 14.2 (12.5) −92.9 (12.1) −107.1 (−141.2 to −73.0) <.0001 
Patients with response <1 eos/HPF — no. (%) 0.0 3 (13.0) 13.0 (−15.72 to 39.73) .1092 
Patients with response ≤6 eos/HPF — no. (%) 0.0 15 (65.2) 65.2 (38.31 to 83.62) <.0001 
Patients with response <15 eos/HPF — no. (%) 0.0 19 (82.6) 82.6 (59.18 to 95.05) <.0001 
EoE-EREFS total score
b
     
Week 12 — no./imputed no. 22/2 23/0   
LS mean change from baseline (SE) −0.3 (0.3) −1.9 (0.3) −1.6 (−2.5 to −0.7) .0006 
EoE-HSS score (excluding lamina propria)
c
      
Total grade (severity) score at Week 12 — 
no./imputed no. 
20/4 22/1   
All LS mean percentage change from baseline 3.2 (6.7) −65.1 (6.3) −68.3 (−86.2 to −50.3) <.0001 
 Placebo  
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
Difference  
vs placebo (95% CI) 
P value vs placebo 
(SE) 
Total stage (extent) score at Week 12 — 
no./imputed no.  
20/4 23/0    
All LS mean percentage change from baseline 
(SE) 
−3.5 (5.0) −58.1 (4.7) −54.6 (−68.1 to −41.0) <.0001 
Distensibility plateau, mm     
Week 12 — no./imputed no.  12/12 12/11   
LS mean change from baseline (SE), mm −1.2 (0.5) 1.8 (0.5) 2.9 (1.7 to 4.2) <.0001 
LS mean percentage change from baseline 
(SE) 
−6.2 (2.7) 11.8 (2.7) 18.0 (10.9 to 25.2) <.0001 
Weekly EEsAI PRO score
d
     
Week 10 — no./imputed no. 13/11 17/6   
 Placebo  
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
Difference  
vs placebo (95% CI) 
P value vs placebo 
LS mean change from baseline (SE) −9.0 (5.6) −22.9 (5.0) −13.9 (−28.5 to 0.8) .0635 
LS mean percentage change from baseline 
(SE) 
–11.3 (9.9) –34.6 (9.1) –23.2 (–49.7 to 3.2) .0850 
Patients with ≥40% improvement — no. (%) 2 (8.3%) 6 (26.1%) 17.8 (−11.5 to 43.6) .1365 
Patients with ≥15-point score improvement — 
no. (%)  
6 (25.0) 11 (47.8) 22.8 (−7.22 to 48.72) .1351 
Patients with ≥30-point score improvement — 
no. (%) 
2 (8.3) 6 (26.1) 17.8 (−11.54 to 43.55) .1365 
Patients with EEsAI score ≤20 — no. (%)     
  At Week 10 1 (4.2) 6 (26.1) 21.9 (2.3 to 41.6) .0479 
 At Week 12 0 (0) 5 (21.7) 21.7 (4.9 to 38.6) .0219 
EoE-QOL-A total scoree     
 Placebo  
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
Difference  
vs placebo (95% CI) 
P value vs placebo 
Week 12 — no./imputed no.  21/3 23/0   
LS mean change from baseline (SE) 0.5 (0.1) 0.8 (0.1) 0.3 (−0.1 to 0.7) .0910 
Missing data were imputed using multiple imputation. EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; EoE-EREFS, Eosinophilic 
Esophagitis Endoscopic Reference Score; EoE-HSS, eosinophilic esophagitis histology scoring system; EoE-QOL-A, Adult Eosinophilic Esophagitis 
Quality of Life; eos/HPF, eosinophils per high-power field; LS, least squares; PRO, patient-reported outcome; SD, standard deviation; SDI, 
Straumann Dysphagia Instrument; SE, standard error; qw, once a week.  
a
SDI PRO total score is the sum of scores of frequency of dysphagia and intensity of dysphagia; total score range 0−9 (higher scores indicate 
worse symptoms). The minimal clinically important difference is 3.30  
bThe EoE-EREFS measures endoscopically identified EoE esophageal mucosal inflammatory and remodeling features; total scores for edema, 
rings, furrows, exudate, stricture range 0−8 (higher scores indicate greater impairment). 
cThe EoE-HSS measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, surface epithelial 
alteration, dyskeratotic epithelial cells, and dilated intercellular spaces; scale 0−63 (higher scores indicate more severe histologic findings). 
d
EEsAI PRO is a 5-component (10-item) measure of dysphagia, swallowing-associated pain, and strategies aimed at avoiding dysphagia episodes; 
total score range 0−100 (higher scores indicate worse symptoms). 
e
EoE-QOL-A questionnaire includes 30 items related to 5 established domains (eating/diet impact, social impact, emotional impact, disease 
anxiety, and swallowing anxiety) of daily life experiences using a 5-point Likert scale. The scores for EoE-QOL-A score is the average score, 
equaled the total score/number of questions (120/30 = 4 for patients without disease). Total scores range from 1 to 5. 
 
Table 3. Key TEAEs During the 12-Week Treatment Period 
n (%) Placebo 
(n = 24) 
Dupilumab 
300 mg qw 
(n = 23) 
≥1 TEAE 15 (63) 18 (78) 
≥1 SAE
a 
0 0 
AEs leading to treatment discontinuation 0 1 (4) 
Deaths 0 0 
Terms with a difference of number of patients 
between two groups ≥3  
  
Injection-site reactions (HLT) 7 (29) 13 (57) 
Injection-site erythema (PT) 2 (8) 8 (35) 
Injection-site inflammation (PT) 0 3 (13) 
Injection-site rash (PT) 0 3 (13) 
Upper respiratory tract infections (HLT)
 
 3 (13) 7 (30) 
Nasopharyngitis (PT) 1 (4) 4 (17) 
Musculoskeletal, connective tissue pain and 
discomfort (HLT) 
0 3 (13) 
AE, adverse event; HLT, MedDRA high-level term; MedDRA, Medical Dictionary for Regulatory Activities; 
PT, MedDRA preferred term; SAE, serious AE; TEAE, treatment-emergent adverse event; qw, once a 
week. 
a
SAEs were considered to be unrelated to the investigational medicinal product; 3 events in 3 patients in 
the dupilumab group were food allergy, creatine phosphokinase elevation, and spontaneous abortion; a 
female patient (aged 30 years) with a prior history of anaphylaxis to tree nuts and moderate allergy to 
milk and eggs developed a sudden episode of throat swelling after ingestion of a vegan shake; the 
episode was resolved with an epinephrine injection. 
 


What you need to know: 
BACKGROUND AND CONTEXT: Dupilumab, a monoclonal antibody against the interleukin 4 
receptor, is effective in treatment of allergic, atopic, and type 2 diseases. We assessed its efficacy 
and safety in patients with eosinophilic esophagitis (EoE). 
 
NEW FINDINGS: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, 
and histologic and endoscopic features of the disease compared with placebo. Dupilumab 
increased esophageal distensibility and was generally well tolerated. 
 
LIMITATIONS: The study was small and of short duration (12 weeks). Further studies are 
required to determine the long-term efficacy and safety of dupilumab in treatment of EoE. 
 
IMPACT: Dupilumab might be a new treatment approach for patients with EoE.  
 
LAY SUMMARY Dupilumab is safe and effective for treatment of EoE, reducing symptoms and 
also correcting clinical and structural abnormalities associated with this disease.  
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This appendix has been provided by the authors to give readers additional information about their work. 
 
Supplement to: Hirano I, Dellon ES, Hamilton JD, et al. Dupilumab Efficacy in Adults With Active 
Eosinophilic Esophagitis: A Randomized, Placebo-Controlled Phase 2 Trial. 
  
2 
 
Dupilumab Efficacy in Adults With Active Eosinophilic Esophagitis: A 
Randomized, Placebo-Controlled Phase 2 Trial 
 
Ikuo Hirano, Evan S. Dellon, Jennifer D. Hamilton, Margaret H. Collins, Kathryn Peterson,  
Mirna Chehade, Alain M. Schoepfer, Ekaterina Safroneeva, Marc E. Rothenberg, Gary W. Falk,  
Yehudith Assouline-Dayan, Qiong Zhao, Zhen Chen, Brian N. Swanson, Gianluca Pirozzi, Leda Mannent, 
Neil M.H. Graham, Bolanle Akinlade, Neil Stahl, George D. Yancopoulos, and Allen Radin. 
 
Author names in bold designate shared co-first authors. 
 
  
3 
 
Table of Contents 
1. Patient eligibility criteria ...................................................................................................................... 5 
1.1 Inclusion criteria ............................................................................................................................ 5 
1.2 Exclusion criteria ............................................................................................................................ 6 
2. Prohibited concomitant medications ................................................................................................... 8 
3. Statistical analysis ................................................................................................................................ 8 
4. Patient narrative 1 ............................................................................................................................. 10 
5. Patient narrative 2 ............................................................................................................................. 11 
6. Tables and figures .............................................................................................................................. 12 
Supplementary Figure 1. Study design .................................................... Error! Bookmark not defined. 
Supplementary Figure 2. CONSORT diagram ........................................... Error! Bookmark not defined. 
Supplementary Figure 3. SDI PRO change from baseline during the 12-week analysis period ........ Error! 
Bookmark not defined. 
Supplementary Figure 4. Individual peak eosinophil count (eos/HPF) at baseline and Week 12..... Error! 
Bookmark not defined. 
Supplementary Figure 5. Peak eosinophil count (eos/HPF) at baseline and Week 12... Error! Bookmark 
not defined. 
Supplementary Figure 6. Proportion of patients with esophageal intraepithelial eosinophil count 
reductions at Week 12 ............................................................................ Error! Bookmark not defined. 
Supplementary Figure 7. EEsAI PRO percent change from baseline during the 12-week analysis period
 ............................................................................................................... Error! Bookmark not defined. 
4 
 
Supplementary Table 1. Summary of Study Endpoints
a
 ...................................................................... 19 
Supplementary Table 2. History of Food Allergy ................................................................................. 22 
Supplementary Table 3. Number of Patients With Available Data for the Primary, Secondary, and 
Exploratory Endpoints by Treatment ................................................................................................. 24 
Supplementary Table 4. Primary, Secondary, and Exploratory Endpoints – All Observed Values ......... 27 
Supplementary Table 5. Sensitivity Analyses for Primary Endpoint ..................................................... 32 
Supplementary Table 6. Key TEAEs During the Entire Study Period Including the 16-Week Follow-up 
Period ................................................................................................................................................ 33 
7. References ........................................................................................................................................ 35 
 
5 
 
1. Patient eligibility criteria  
1.1 Inclusion criteria 
1. Male or female, 18 to 65 years old 
2. Documented diagnosis of EoE by endoscopy prior to or at screening 
Note: Must include a demonstration of intraepithelial eosinophilic infiltration (peak cell count 
≥15 eosinophils/high power field [eos/HPF] [400X, 0.3mm
2
]) from esophageal biopsy specimens 
from endoscopy performed no more than 2 weeks after at least 8 weeks of treatment with high-
dose (or twice-daily dosing) proton pump inhibitors (PPIs) 
3. History (by patient report) of, on average, at least 2 episodes of dysphagia (with intake of solids 
off anti-inflammatory therapy) per week in the 4 weeks prior to screening and, on average, at 
least 2 episodes of documented dysphagia per week in the weeks between screening and 
baseline; dysphagia is defined as trouble swallowing solid food, or having solid food stick, by 
patient report 
4. Must remain on a stabilized diet for at least 6 weeks prior to screening and during the course of 
the study; stable diet is defined as no initiation of single or multiple elimination diets or 
reintroduction of previously eliminated food groups 
5. SDI PRO score ≥5 at screening and baseline  
6. Documented history of or presence of 1 or more of any of the following:  
• Allergic disease (eg, allergic asthma, allergic rhinitis, atomic dermatitis, or food allergies) 
• Blood eosinophil count ≥0.25 GI/L  
• Serum total immunoglobulin E (IgE) ≥100 kU/L 
7. Willing and able to comply with all clinic visits and study-related procedures 
8. Able to understand and complete study-related questionnaires 
9. Provide signed informed consent 
10. Endoscopy with photographs performed at screening, with a demonstration of intraepithelial 
eosinophilic infiltration (peak cell count ≥15 eos/HPF) in at least 2 of the 3 biopsied esophageal 
regions (proximal, mid, or distal) 
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1.2 Exclusion criteria 
1. Prior participation in a dupilumab (anti–interleukin-4R) clinical trial 
2. Other causes of esophageal eosinophilia or the following diseases: hypereosinophilic 
syndromes, Churg-Strauss vasculitis, or eosinophilic gastroenteritis  
3. History of achalasia, active Helicobacter pylori infection, Crohn’s disease, ulcerative colitis, celiac 
disease, or prior esophageal surgery prior to screening 
4. Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9mm to 10mm) 
upper endoscope, or any critical esophageal stricture that required dilation at screening 
5. History of bleeding disorders or esophageal varices 
6. Use of chronic aspirin, nonsteroidal agents, or anticoagulants within 2 weeks prior to screening; 
patients should not stop these agents solely to become eligible for entry into this study 
7. Treatment with an investigational drug within 2 months or within 5 half-lives (if known), 
whichever is longer, prior to screening 
8. Use of systemic glucocorticoids within 3 months or swallowed topical glucocorticoids within 6 
weeks prior to screening 
9. Use of inhaled or nasal glucocorticoids within 3 months prior to screening and during the study, 
except stable dose for at least 3 months prior to screening biopsy (which cannot be changed 
during the study) 
10. Treatment with oral immunotherapy (OIT) within 6 months prior to screening 
11. Allergen immunotherapy (sublingual immunotherapy [SLIT] and/or subcutaneous 
immunotherapy [SCIT]), unless on stable dose for at least 1 year prior to screening 
12. The following treatments within 3 months before the screening visit, or any condition that, in 
the opinion of the investigator, is likely to require such treatment(s) during the 3 months of 
study treatment: 
• Systemic immunosuppressive/immunomodulating drugs (eg, omalizumab, cyclosporine, 
mycophenolate mofetil, interferon gamma [IFN-γ], Janus kinase inhibitors, azathioprine, 
methotrexate, leukotriene inhibitors (except stable dose for at least 3 months prior to 
screening) 
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13. Diagnosed with active parasitic infection; suspected parasitic infection, unless clinical and (if 
necessary) laboratory assessments have ruled out active infection before randomization 
14. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or 
antifungals within 1 month prior to screening 
15. Use of oral antibiotics/anti-infectives within 2 weeks prior to screening 
16. Known or suspected immunosuppression, including history of invasive opportunistic infections 
(eg, tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, 
coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise 
recurrent infections of abnormal frequency, or prolonged infections suggesting an 
immunocompromised status, as judged by the investigator 
17. Known history of human immunodeficiency virus (HIV) infection  
18. Positive or indeterminate hepatitis B surface antigen (HBsAg) or hepatitis C antibody at 
screening  
19. Elevated transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase 
[AST]) more than 3 times the upper limit of normal (ULN) at screening 
20. History of malignancy within 5 years prior to screening, except completely treated in situ 
carcinoma of the cervix and completely treated and resolved nonmetastatic squamous or basal 
cell carcinoma of the skin 
21. History of patient-reported alcohol or drug abuse within 6 months prior to screening 
22. Any other medical or psychological condition including relevant laboratory abnormalities at 
screening that, in the opinion of the investigator, suggest a new and/or insufficiently understood 
disease, may present an unreasonable risk to the study patient as a result of his/her 
participation in this clinical trial, may make the patient’s participation unreliable, or may 
interfere with study assessments; the specific justification for patients excluded under this 
criterion will be noted in study documents (chart notes, case report form [CRF], etc.) 
23. Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect the 
patient’s participation in the study 
24. Planned or anticipated use of any prohibited medications or procedures during study treatment 
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25. Treatment with a live (attenuated) vaccine within 3 months prior to screening 
26. Patient or his/her immediate family is a member of the investigational team 
27. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed 
during the study 
28. Women unwilling to use adequate birth control, if of reproductive potential* and sexually active 
(adequate birth control is defined as agreement to consistently practice an effective and 
accepted method of contraception for the duration of the study and for 120 days after last dose 
of study drug; these include hormonal contraceptives, an intrauterine device, or double barrier 
contraception (ie, condom + diaphragm), or male partner with documented vasectomy  
* For females, menopause is defined as at least 12 consecutive months without menses (if in 
question, follicle stimulating hormone of ≥25 U/mL must be documented); hysterectomy, 
bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable, and 
women with these documented conditions are not required to use additional contraception 
2. Prohibited concomitant medications 
Prohibited concomitant medications included medications used for the treatment of EoE, allergen 
immunotherapy, live attenuated vaccines, and any investigational drug other than dupilumab. Patients 
who were not using a proton pump inhibitor (PPI) in the 8 weeks prior to screening could not start PPI 
therapy prior to the end-of-treatment visit. 
3. Statistical analysis 
Efficacy data through Week 12 were set to missing for all time points subsequent to the use of rescue 
treatment, and then the missing value imputed using multiple imputation (MI). Missing data from the 
full analysis set (FAS) was imputed 50 times to generate 50 complete datasets by using the SAS MI 
procedure following 2 steps: 1) the monotone missing pattern was induced by the Markov Chain Monte 
Carlo method in the MI procedure: if a patient had a missing value for a variable at a visit, then the 
values at all subsequent visits for the same variable were all missing for the patient; 2) the missing data 
at subsequent visits were imputed using the regression method for the monotone pattern with 
adjustment for covariates including treatment groups and baseline SDI score. The imputation model 
included the covariates that were included in the analysis of covariance (ANCOVA) model (consisting of 
the treatment group and the baseline SDI value), and observed post-baseline efficacy values up to Week 
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10. Data from each of the 50 complete datasets were analyzed using ANCOVA with treatment group as 
fixed effect and baseline SDI value as continuous covariate. The SAS MIANALYZE procedure was used to 
generate valid statistical inferences by combining results from these multiple analyses using Rubin’s 
formula. 
The ANCOVA model generated least squares (LS) mean changes from baseline to Week 10, and other 
time points for each treatment group, with the corresponding standard error, confidence interval, and P 
value for treatment comparisons. Four prespecified sensitivity analyses were performed for the primary 
endpoint, with various methods to handle missing data: 1) MI followed by ANCOVA based on all 
observed data regardless of the use of rescue medication; 2) ANCOVA with the efficacy dataset to 
missing after the use of rescue medication, then the post-baseline last observation carried forward 
(LOCF) method was used to impute missing data; 3) ANCOVA with efficacy dataset to missing after the 
use of rescue medication, then the post-baseline worst observation carried forward (WOCF) method 
was used to impute missing data; and 4) ANCOVA based on all observed data regardless of the use of 
rescue medication. 
Upon blinded data review, it was noted that there was an e-diary malfunction resulting in fewer data 
being collected at Week 12 than at Week 10 for SDI. Thus, while the study was still blinded, the SDI 
primary endpoint in the protocol was amended from Week 12 to Week 10. 
The continuous secondary and exploratory efficacy endpoints were analyzed using the same approach 
as that used for the primary endpoint, with the exception that the imputation (used to perform MI) and 
ANCOVA models included each endpoint’s relevant baseline value in addition to the baseline SDI as 
continuous covariates. 
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4. Patient narrative 1 
The following adverse event of a nonserious moderate nail disorder leading to withdrawal from the 
study was received by an investigator on March 23, 2016. 
A 27-year-old female patient with eosinophilic esophagitis was randomized to receive study drug 
REGN668 (loading dose 600 mg SC, followed by 300 mg SC weekly thereafter).  
 
On March 23, 2016, after 37 days of study treatment, the patient experienced a nonserious moderate 
nail disorder (verbatim term: left index fingernail indentation) after receiving 5 weekly doses of 
dupilumab. The patient received her sixth dose on Day 38, however, the event led to permanent 
discontinuation of the study drug afterward. The event was not symptomatic and not associated with an 
infection or any other symptoms. The cause of the event was unknown. The event was assessed by the 
investigator to be unrelated to the study drug. The event was ongoing at the time of her last study visit. 
Additional adverse events were reported for the patient during treatment, including injection site 
reactions and back acne, and the nail disorder was considered the deciding factor, leading to the patient 
choosing to withdraw from the study. The investigator was comfortable with her continuing with the 
study and did not withdraw her for any adverse event.   
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5. Patient narrative 2 
The following serious adverse event of a spontaneous abortion was received by an investigator on 
December 23, 2016. 
A 44-year-old female patient with eosinophilic esophagitis was randomized on September 30, 2016 to 
receive study drug REGN668 (loading dose 600 mg SC, followed by 300 mg SC weekly thereafter). The 
patient's medical history included cervical cancer, cervix removal, attention deficit disorder, dry eye 
syndrome, and allergies (environmental and food). 
On December 22, 2016, after 83 days of study treatment, the patient had an initial positive serum, urine 
pregnancy test with serum human chorionic gonadotropin of 252.4 mIU/mL (normal range 0–5 
mIU/mL). Pregnancy was confirmed the same day. The number of weeks that the patient had been 
pregnant at the time of diagnosis was unknown. Use of contraceptives was not reported. The date of the 
patient's last menstrual period was not reported and the estimated date of delivery was unknown. 
Termination was reported as possible with more information pending. Information regarding previous 
pregnancies was not reported. On December 26, 2016, the patient had a spontaneous abortion. It was 
reported that the patient had planned a termination with her gynecologist but had spontaneously 
aborted prior to the planned termination. Based on the patient’s history of cervical surgery, the abortion 
was not unexpected, and the patient stated that she had no intentions to have a child. The patient had 
an unspecified number of full-term births and an unknown number of spontaneous abortions. On 
January 20, 2017, a urine pregnancy test was negative.  
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6. Tables and figures 
 
Supplementary Figure 1. Study design. Patients received weekly injections of study drug from Day 1 to 
Week 12 (with the last dose at Week 11). Follow-up visits occured every 4 weeks. SC, subcutaneous. 
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Supplementary Figure 2. CONSORT diagram. 
 
  
Assessed for eligibility (N = 80 )
Screen failures (N = 33) Randomized (N = 47)
Assigned to and received placebo (n = 24)
Completed randomized treatment (n = 20)
Discontinued randomized treatment* (n = 4)
Adverse event (n = 0)
Lack of efficacy (n = 0)
Protocol noncompliance (n = 1)
Other (n = 3)
*During randomized treatment period
Analyzed for efficacy (n = 24)
Analyzed for safety (n = 24)
Assigned to and received dupilumab (n = 23)
Completed randomized treatment (n = 22)
Discontinued randomized treatment* (n = 1)
Adverse event (n = 1)
Lack of efficacy (n = 0)
Protocol noncompliance (n = 0)
Other (n = 0)
*During randomized treatment period
Analyzed for efficacy (n = 23)
Analyzed for safety (n = 23)
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Supplementary Figure 3. SDI PRO change from baseline during the 12-week analysis period. *P<.05 vs 
placebo. LS, least squares; PRO, patient-reported outcome; qw, weekly; SE, standard error; SDI, 
Straumann Dysphagia Instrument. Missing data were imputed using multiple imputation. 
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Supplementary Figure 4. Individual peak eosinophil count (eos/HPF) at baseline and Week 12. Eos/HPF, 
eosinophils per high-power field; qw, weekly. 
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Supplementary Figure 5. Peak eosinophil count (eos/HPF) at baseline and Week 12. P = comparision of 
change from baseline to Week 12. Eos/HPF, eosinophils per high-power field (0.3 mm
2
); qw, weekly; SD, 
standard deviation. 
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Supplementary Figure 6. Proportion of patients with esophageal intraepithelial eosinophil count 
reductions at Week 12. Eos/HPF, eosinophils per high-power field; qw, weekly. 
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Supplementary Figure 7. EEsAI PRO percent change from baseline during the 12-week analysis period. 
EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; LS, least squares; PRO, patient-reported 
outcome; qw, weekly; SE, standard error. Missing data were imputed using multiple imputation. 
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Supplementary Table 1. Summary of Study Endpoints
a
 
Endpoint Timeframe 
PRIMARY ENDPOINT  
Change in SDI PRO score
b
 Week 10 
SECONDARY ENDPOINTS  
Percentage change in weekly EEsAI PRO score
c
 Weeks 10 and 12  
Change in weekly EEsAI PRO score
c
 Weeks 10 and 12 
Percentage change in SDI PRO score
b
 Weeks 10 and 12 
Change in SDI PRO scoreb Week 12 
Change in EoE-QOL-A PRO score
d
 Week 12 
Percentage of patients with SDI PRO response, where 
response is defined as a decrease of ≥3 points compared 
with baseline
b
 
Week 10 
Percentage of patients with ≥40% improvement in EEsAI 
PRO score
c
 
Week 10 
Percentage change in overall peak esophageal 
intraepithelial eos/HPF (400X)  
Week 12 
Change in EoE-EREFS (endoscopy visual anatomical 
score)
e
 
Week 12 
Percentage of patients with use of rescue medication or 
procedure (eg, esophageal dilation)  
Week 12 
Safety  
Incidence of treatment-emergent AEs 
 
12-week treatment period and follow-up 
(Week 28) 
Exploratory endpoints  
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Change in mean esophageal intraepithelial eosinophil 
count (eos/HPF) (calculated using peak count from each 
esophageal site)  
Week 12 
Proportion of patients with esophageal intraepithelial 
eosinophil count <1 eos/HPF 
Week 12 
Change in Collins Histology Score
f
 Week 12 
Change in esophageal distensibility plateau as measured 
by functional lumen imaging  
Week 12 
EoE, eosinophilic esophagitis; EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; EoE-EREFS, 
Eosinophilic Esophagitis Endoscopic Reference Score; EoE-HSS, eosinophilic esophagitis histology scoring 
system; EoE-QOL-A, Adult Eosinophilic Esophagitis Quality of Life Questionnaire; PRO, patient-reported 
outcome; SDI, Straumann Dysphagia Instrument. 
a
There was no adjustment of multiplicity for the secondary efficacy endpoints. 
b
SDI PRO total score is the sum of scores of frequency of dysphagia and intensity of dysphagia; total 
score range 0−9 (higher scores indicate worse symptoms). The minimal clinically important difference is 
3.
1
 
 
c
EEsAI PRO is a 5-component (10 or 11 items) measure of dysphagia, swallowing-associated pain, and 
strategies aimed at avoiding dysphagia episodes; total score range 0−100 (higher scores indicate worse 
symptoms).
2
  
d
EoE-QOL-A questionnaire includes 30 items related to 5 established domains (eating/diet impact, social 
impact, emotional impact, disease anxiety, and swallowing anxiety) of daily life experiences using a 5-
point Likert scale. The EoE-QOL-A score is the average obtained by dividing the total score by the 
number of questions (for patients without disease, 120/30 = 4). Total scores range from 1 to 5.
3
 
 
e
The EoE-EREFS measures endoscopically identified EoE esophageal mucosal inflammatory and 
remodeling features; total scores for edema, rings, furrows, exudate, stricture range 0−8 (higher scores 
indicate greater impairment).
4
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f
The EoE-HSS measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil 
surface layering, surface epithelial alteration, dyskeratotic epithelial cells, and dilated intercellular 
spaces; scale 0−63 (higher scores indicate more severe histologic findings).
5
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Supplementary Table 2. History of Food Allergy 
Condition, n (%) Placebo qw 
(n = 24) 
Dupilumab 300 mg qw 
(n = 23) 
Patients with at least one food allergy 
history 
17 (70.8) 14 (60.9) 
Allergy to tree nuts 8 (33.3) 7 (30.4) 
Allergy to soy 7 (29.2) 5 (21.7) 
Allergy to milk 6 (25.0) 5 (21.7) 
Allergy to wheat 6 (25.0) 5 (21.7) 
Allergy to shell fish 7 (29.2) 3 (13.0) 
Allergy to eggs 6 (25.0) 3 (13.0) 
Allergy to peanuts 5 (20.8) 3 (13.0) 
Allergy to fish 5 (20.8) 0 
Allergy to any other food: corn 1 (4.2) 3 (13.0) 
Allergy to sesame or mustard seed 2 (8.3) 2 (8.7) 
Allergy to any other food: peas 2 (8.3) 1 (4.3) 
Allergy to any other food: barley 1 (4.2) 1 (4.3) 
Allergy to any other food: oat 1 (4.2) 1 (4.3) 
Allergy to any other food: pea 1 (4.2) 1 (4.3) 
Allergy to any other food: all fruit 0 1 (4.3) 
Allergy to any other food: all melons 1 (4.2) 0 
Allergy to any other food: apple 1 (4.2) 0 
Allergy to any other food: avocado 1 (4.2) 0 
Allergy to any other food: banana 1 (4.2) 0 
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Allergy to any other food: beef 1 (4.2) 0 
Allergy to any other food: brewer's yeast 1 (4.2) 0 
Allergy to any other food: carrot 0 1 (4.3) 
Allergy to any other food: carrots 0 1 (4.3) 
Allergy to any other food: cashew, walnut, 
coconut, avocado 
1 (4.2) 0 
Allergy to any other food: celery 0 1 (4.3) 
Allergy to any other food: chocolate 0 1 (4.3) 
Allergy to any other food: cinnamon, melon 1 (4.2) 0 
Allergy to any other food: coconut, carrot, 
all melons, tomato 
1 (4.2) 0 
Allergy to any other food: cucumber 0 1 (4.3) 
Allergy to any other food: green bean 0 1 (4.3) 
Allergy to any other food: mushroom flavor 1 (4.2) 0 
Allergy to any other food: oat 0 1 (4.3) 
Allergy to any other food: pineapple, kiwi 0 1 (4.3) 
Allergy to any other food: potato 0 1 (4.3) 
Allergy to any other food: raspberry 1 (4.2) 0 
Allergy to any other food: squash 0 1 (4.3) 
Allergy to any other food: strawberry 0 1 (4.3) 
Allergy to any other food: tomato 1 (4.2) 0 
Allergy to any other food: turkey 0 1 (4.3) 
Allergy to any other food: watermelon, 
tomato, garlic, coconut 
1 (4.2) 0 
The table is sorted in descending order of overall frequency of food allergy. 
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Supplementary Table 3. Number of Patients With Available Data for the Primary, Secondary, and 
Exploratory Endpoints by Treatment 
Efficacy variable Time 
point 
Treatment N at 
baseline 
Patients 
with 
observed 
value, n (%) 
Patients 
discontinued 
from the study 
treatment, n 
(%) 
Patients 
with 
missing 
value, n 
(%) 
SDI PRO
a
 Week 
10 
Placebo  24 14 (58) 4 (17) 10 (42) 
 Week 
10 
Dupilumab 
300 mg qw 
23 17 (74) 1 (4) 6 (26) 
Peak esophageal 
intraepithelial 
eosinophil count 
Week 
12 
Placebo  24 22 (92) 4 (17) 2 (8) 
 Week 
12 
Dupilumab 
300 mg qw 
23 23 (100) 1 (4) 0 (0) 
EoE-EREFS
b
 Week 
12 
Placebo  24 22 (92) 4 (17) 2 (8) 
 Week 
12 
Dupilumab 
300 mg qw 
23 23 (100) 1 (4) 0 (0) 
EoE-HSS grade
c
 Week 
12 
Placebo  24 20 (83) 4 (17) 4 (17) 
 Week 
12 
Dupilumab 
300 mg qw 
23 22 (96) 1 (4) 1 (4) 
EoE-HSS stage
c
 Week 
12 
Placebo  24 20 (83) 4 (17) 4 (17) 
 Week 
12 
Dupilumab 
300 mg qw 
23 23 (100) 1 (4) 0 (0) 
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Efficacy variable Time 
point 
Treatment N at 
baseline 
Patients 
with 
observed 
value, n (%) 
Patients 
discontinued 
from the study 
treatment, n 
(%) 
Patients 
with 
missing 
value, n 
(%) 
Distensibility  Week 
12 
Placebo  24 12 (50) 4 (17) 12 (50) 
 Week 
12 
Dupilumab 
300 mg qw 
23 12 (52) 1 (4) 11 (48) 
EEsAI PRO
d
 Week 
10 
Placebo  24 13 (54) 4 (17) 11 (46) 
 Week 
10 
Dupilumab 
300 mg qw 
23 17 (74) 1 (4) 6 (26) 
EoE-QOL-A
e
 Week 
12 
Placebo  24 21 (87.5) 4 (17) 3 (12.5) 
 Week 
12 
Dupilumab 
300 mg qw 
23 23 (100) 1 (4) 0 (0) 
EoE, eosinophilic esophagitis; EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; EoE-EREFS, 
Eosinophilic Esophagitis Endoscopic Reference Score; EoE-HSS, eosinophilic esophagitis histology scoring 
system; EoE-QOL-A, Adult Eosinophilic Esophagitis Quality of Life Questionnaire; qw, weekly; PRO, 
patient-reported outcome; SDI, Straumann Dysphagia Instrument. 
a
SDI PRO total score is the sum of scores of frequency of dysphagia and intensity of dysphagia; total 
score range 0−9 (higher scores indicate worse symptoms). The minimal clinically important difference is 
3.
1 
bThe EoE-EREFS measures endoscopically identified EoE esophageal mucosal inflammatory and 
remodeling features; total scores for edema, rings, furrows, exudate, stricture range 0−8 (higher scores 
indicate greater impairment).4  
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c
The EoE-HSS measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil 
surface layering, surface epithelial alteration, dyskeratotic epithelial cells, and dilated intercellular 
spaces; scale 0−63 (higher scores indicate more severe histologic findings).
5
  
d
EEsAI PRO is a 5-component (10 or 11 item) measure of dysphagia, swallowing-associated pain, and 
strategies aimed at avoiding dysphagia episodes; total score range 0−100 (higher scores indicate worse 
symptoms).
2
 
eEoE-QOL-A questionnaire includes 30 items related to 5 established domains (eating/diet impact, social 
impact, emotional impact, disease anxiety, and swallowing anxiety) of daily life experiences using a 5-
point Likert scale. The EoE-QOL-A score is the average obtained by dividing the total score by the 
number of questions (for patients without disease, 120/30 = 4). Total scores range from 1 to 5.
3
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Supplementary Table 4. Primary, Secondary, and Exploratory Endpoints – All Observed Values 
 Placebo  
(n = 24) 
Dupilumab 300 mg 
qw 
(n = 23) 
Difference  
vs placebo (95% 
CI) 
P value versus 
placebo 
SDI PRO score
a
     
Week 10 — no. 14 17   
LS mean change from 
baseline (SE) 
–1.1 (0.67) –3.2 (0.61) –2.2 (–4.06 to –
0.33) 
.0226 
LS mean percentage 
change from baseline 
(SE) 
–15.3 (10.57) –49.3 (9.59) –34.1 (–63.34 to –
4.84) 
.0240 
Peak esophageal 
intraepithelial 
eosinophil count 
(eos/HPF)  
    
Week 12 — no. 22 23   
LS mean change 
from baseline (SE) 
–9.7 (9.65) –96.4 (9.44) –86.7 (–114.00 to 
–59.37) 
<.0001 
LS mean % change 
from baseline (SE) 
12.3 (12.31) –93.3 (12.04) –105.6 (–140.47 to 
–70.79) 
<.0001 
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 Placebo  
(n = 24) 
Dupilumab 300 mg 
qw 
(n = 23) 
Difference  
vs placebo (95% 
CI) 
P value versus 
placebo 
EoE-EREFS total score
b
     
Week 12 — no. 22 23   
LS mean change 
from baseline (SE) 
–0.3 (0.33) –1.9 (0.32) –1.6 (–2.53 to –
0.65) 
.0015 
EoE-HSS score 
(excluding lamina 
propria)
c 
 
    
Total grade (severity) 
score at Week 12 — 
no. 
20 22   
All LS mean 
percentage change 
from baseline (SE) 
2.3 (6.48) –65.4 (6.17) –67.7 (–85.84 to –
49.51) 
<.0001 
Total stage (extent) 
score at Week 12 — 
no.  
20 23   
All LS mean 
percentage change 
–3.4 (4.92) –58.6 (4.58) –55.1 (–68.76 to –
41.53) 
<.0001 
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 Placebo  
(n = 24) 
Dupilumab 300 mg 
qw 
(n = 23) 
Difference  
vs placebo (95% 
CI) 
P value versus 
placebo 
from baseline (SE) 
Distensibility plateau, 
mm 
    
Week 12 — no. 12 12   
LS mean change 
from baseline (SE), 
mm 
–1.01 (0.46) 1.85 (0.46) 2.85 (1.48 to 4.22) .0003 
LS mean percentage 
change from 
baseline (SE) 
–5.6 (3.02) 13.0 (3.02) 18.5 (9.58 to 
27.47) 
.0003 
Weekly EEsAI PRO 
score
d
 
    
Week 10 — no. 13 17   
LS mean change 
from baseline (SE) 
–11.1 (6.65) –27.8 (5.81) –16.7 (–34.91 to 
1.46) 
.0699 
LS mean percentage 
change from 
baseline (SE) 
–16.7 (11.21) –42.2 (9.80) –25.6 (–56.23 to 
5.06) 
.0981 
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 Placebo  
(n = 24) 
Dupilumab 300 mg 
qw 
(n = 23) 
Difference  
vs placebo (95% 
CI) 
P value versus 
placebo 
EoE-QOL-A total 
score
e
 
    
Week 12 — no. 21 23   
LS mean change 
from baseline (SE) 
0.44 (0.143) 0.79 (0.137) 0.35 (–0.054 to 
0.751) 
.0879 
 
EEsAI, symptom-based Eosinophilic Esophagitis Activity Index; EoE-EREFS, Eosinophilic Esophagitis 
Endoscopic Reference Score; EoE-HSS, eosinophilic esophagitis histology scoring system; EoE-QOL-A, 
Adult Eosinophilic Esophagitis Quality of Life; eos/HPF, eosinophils per high-power field; LS, least 
squares; PRO, patient-reported outcome; SD, standard deviation; SDI, Straumann Dysphagia Instrument; 
SE, standard error; qw, once a week.  
aSDI PRO total score is the sum of scores of frequency of dysphagia and intensity of dysphagia; total 
score range 0−9 (higher scores indicate worse symptoms). The minimal clinically important difference is 
3.
30
  
bThe EoE-EREFS measures endoscopically identified EoE esophageal mucosal inflammatory and 
remodeling features; total scores for edema, rings, furrows, exudate, stricture range 0−8 (higher scores 
indicate greater impairment). 
cThe EoE-HSS measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil 
surface layering, surface epithelial alteration, dyskeratotic epithelial cells, and dilated intercellular 
spaces; scale 0−63 (higher scores indicate more severe histologic ﬁndings). 
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d
EEsAI PRO is a 5-component (10-item) measure of dysphagia, swallowing-associated pain, and 
strategies aimed at avoiding dysphagia episodes; total score range 0−100 (higher scores indicate worse 
symptoms). 
e
EoE-QOL-A questionnaire includes 30 items related to 5 established domains (eating/diet impact, social 
impact, emotional impact, disease anxiety, and swallowing anxiety) of daily life experiences using a 5-
point Likert scale. The scores for EoE-QOL-A score is the average score, equaled the total score/number 
of questions (120/30 = 4 for patients without disease). Total scores range from 1 to 5. 
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Supplementary Table 5. Sensitivity Analyses for Primary Endpoint 
SDI score at Week 
10 by missing data 
imputation method 
Placebo 
(n = 24) 
Dupilumab    
300 mg qw 
(n = 23) 
LS mean difference  
vs placebo (95% 
CI) 
P value vs 
placebo 
LOCF method
a
 −1.2 (0.48) −3.0 (0.49) −1.8 (−3.20 to 
−0.43) 
.0112 
WOCF method
b
 −0.9 (0.48) −2.7 (0.48) −1.8 (−3.16 to 
−0.40) 
.0127 
All observed valuesc −1.1 (0.67) −3.2 (0.61) −2.2 (−4.06 to 
−0.33) 
.0226 
a
LOCF method: data were set to missing after rescue treatment. Missing values were imputed using the 
LOCF method. In the event that patients only had baseline values without any post-baseline values, their 
baseline values were carried forward to impute post-baseline missing values.  
b
WOCF method: data were set to missing after rescue treatment. Missing values were imputed using the 
WOCF method. In the event that patients only had baseline values without any post-baseline values, 
WOCF would not impute for post-baseline missing values. 
cAll observed values: all observed values regardless of whether rescue medication was used were 
included in the analysis, with no imputation for missing values. 
LOCF, last observation carried forward; WOCF, worst observation carried forward; SDI, Straumann 
Dysphagia Instrument. 
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Supplementary Table 6. Key TEAEs During the Entire Study Period Including the 16-Week Follow-up 
Period 
n (%)  
Placebo 
(n = 24) 
Dupilumab 
300 mg qw 
(n = 23) 
≥1 TEAE 16 (67) 21 (91) 
≥1 SAE
a 
0 3 (13) 
AEs leading to treatment discontinuation 0 1 (4) 
Deaths 0 0 
Terms with a difference of number of patients 
between two groups ≥3  
  
Injection-site reaction (HLT) 7 (29) 13 (57) 
Injection-site erythema (PT) 2 (8) 8 (35) 
Injection-site inflammation (PT) 0 3 (13) 
Injection-site rash (PT) 0 3 (13) 
Upper respiratory tract infection (HLT)
 
 6 (25) 9 (39) 
Nasopharyngitis (PT) 2 (8) 5 (22) 
Musculoskeletal, connective tissue pain and 
discomfort (HLT) 
0 4 (17) 
AE, adverse event; HLT, MedDRA high-level term; MedDRA, Medical Dictionary for Regulatory Activities; 
PT, MedDRA preferred term; SAE, serious AE; TEAE, treatment-emergent adverse event; qw, once a 
week. 
a
SAEs were considered to be unrelated to the investigational medicinal product; 3 events in 3 patients in 
the dupilumab group were food allergy, creatine phosphokinase elevation, and spontaneous abortion; a 
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female patient (aged 30 years) with a prior history of anaphylaxis to tree nuts and moderate allergy to 
milk and eggs developed a sudden episode of throat swelling after ingestion of a vegan shake; the 
episode was resolved with an epinephrine injection. 
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